Abstract Number: 159 • 2014 ACR/ARHP Annual Meeting
Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant or Unresponsive to non-Steriodal Anti-Inflammatory drugs and/or Colchicine: Safety and Efficacy Results from Long Term Follow-up
Background/Purpose Frequently flaring acute gouty arthritis (GA) patients (pts), in whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective, need effective alternative treatments.1 Canakinumab…Abstract Number: 157 • 2014 ACR/ARHP Annual Meeting
Can We Diagnose Acute Gout without Joint Aspiration? Results of a Prospective Study of 112 Patients Presenting with Acute Arthritis
Background/Purpose The gold standard for the diagnosis of acute MSU induced arthritis is crystal identification by microscopy after joint aspiration. Alternative diagnostic tools that have…Abstract Number: 176 • 2014 ACR/ARHP Annual Meeting
Comparative Cardiovascular (CV) Risk and Outcomes Among Patients with Gout, Osteoarthritis (OA), or Both
Background/Purpose: Gout is associated with increased CV risk, both dependent on, and independent of traditional CV risk factors. Recent studies suggest that OA, traditionally considered non-inflammatory,…Abstract Number: 174 • 2014 ACR/ARHP Annual Meeting
Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study
Background/Purpose: Gouty arthritis (GA) patients who experience frequent flares and have comorbidities have limited treatment options. Canakinumab (CAN), a selective, human, anti-interleukin1β monoclonal antibody, has…Abstract Number: 173 • 2014 ACR/ARHP Annual Meeting
Self-Management Education for Patients with Gout: A Review of Existing Resources
Background/Purpose Inadequate patient self-management education resources may contribute to poor management and outcomes for gout. Patient education resources need to be easy to read and…Abstract Number: 172 • 2014 ACR/ARHP Annual Meeting
Sleep Apnea and Risk of Incident Gout: A Population-Based Body-Mass Index Matched Cohort Study
Background/Purpose: Sleep apnea is common among obese individuals with comorbidities (up to ~30%), a typical profile of gout patients. Since hypoxia associated with sleep apnea…Abstract Number: 175 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Acute Gouty Arthritis Patients with Chronic Kidney Disease Stage Greater Than or Equal to 3: A Post-Hoc Analysis of 12-Week Data
Background/Purpose: Chronic kidney disease (CKD) limits the treatment options in acute gouty arthritis (GA) patients due to intolerance and contraindications to available therapies. Efficacy and…Abstract Number: 156 • 2014 ACR/ARHP Annual Meeting
Colchicine and the Risk of Acute Cardiovascular (CV) Events Among Gout Patients: The New York Department of Veterans Affairs Retrospective Cohort Study
Background/Purpose: Gout patients are at increased risk for CV disease, possibly owing to chronic inflammation. Colchicine is commonly used in gout, and inhibits inflammatory cell…Abstract Number: 155 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis of HLA-B5801 Genotyping in the Treatment of Gout Patients with Chronic Renal Insufficiency in Korea
Background/Purpose Allopurinol-induced severe cutaneous adverse reactions (SCARs) are relatively rare, but cause high rates of morbidity and mortality. Studies have shown that the HLA-B5801 allele…Abstract Number: 152 • 2014 ACR/ARHP Annual Meeting
Subclinical Synovial Inflammation in Gout
Background/Purpose Gout is poorly managed in the community. Long standing poorly controlled gout can lead into progressive destructive arthropathy, decreased quality of life and increased…Abstract Number: 118 • 2014 ACR/ARHP Annual Meeting
Difficult to Treat Gouty Arthritis Associated with Poor Health Related Quality of Life and High Resource Utilization: Post- Hoc Analysis
Background/Purpose: Difficult-to-treat (DTT) group in the MOTION study included symptomatic refractory gouty arthritis (RGA) patients with ≥3 flares, refractory to NSAIDs/colchicine/steroids or to uric acid…Abstract Number: 117 • 2014 ACR/ARHP Annual Meeting
Predictors of Gout Flares in a US Managed Care Setting
Background/Purpose Gout is the most common inflammatory arthritis in the US, and acute gout flares are among the most painful events experienced by humans. The…Abstract Number: 105 • 2014 ACR/ARHP Annual Meeting
Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey
Background/Purpose: Gout is caused by chronic high serum uric acid (SUA) levels (i.e., hyperuricemia), which leads to the deposition of monosodium urate crystals in musculoskeletal…Abstract Number: 46 • 2014 ACR/ARHP Annual Meeting
Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in Patients with Gout
Background/Purpose: Hyperuricemia and gout are associated with an increased risk of type 2 diabetes (T2D). Xanthine oxidase inhibitors (XOI), allopurinol and febuxostat, are the main…Abstract Number: 44 • 2014 ACR/ARHP Annual Meeting
Physical Function, Hyperuricemia and Gout in Older Adults
Background/Purpose: The prevalence of gout is higher in older adults than in younger adults and these patients are at risk of physical disability. We sought…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »